Gilead Sciences Inc
GILD#97 of 134 by buybacksNASDAQ · Healthcare · Drug Manufacturers - General · USA
gilead.comBuybacks · TTM to Jun 2026$1.44Blatest four quarters
Buyback yield0.8%repurchases ÷ market cap
Dividends · TTM to Jun 2026$4.07Bdividend yield 2.2%
Shareholder yield2.9%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−1.5%1.24B shares (2026)
Buybacks ÷ free cash flow11%payout incl. dividends 42%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $1.92B | $4.00B | $9.46B |
| FY2024Dec 2024 | $1.15B | $3.92B | $10.3B |
| FY2023Dec 2023 | $1.00B | $3.81B | $7.42B |
| FY2022Dec 2022 | $1.40B | $3.71B | $8.34B |
| FY2021Dec 2021 | $546M | $3.60B | $10.8B |
| FY2020Dec 2020 | $1.58B | $3.45B | $7.52B |
| FY2019Dec 2019 | $1.75B | $3.22B | $8.32B |
Repurchases in FY2025 were +67.1% versus the prior year.
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of ad…
- Market cap
- $187B
- P/E (trailing)
- —
- Fiscal year end
- December
- ISIN
- US3755581036
- Reporting currency
- USD
- Data updated
- Oct 10, 2026